A Wisconsin-based startup with ties to University of Wisconsin, in March 2019 Pantherics Incorporated, merged with San Diego based Bio33 Degrees, Inc., creating a unified drug discovery and development platform to target GABAAR in peripheral tissues. With the firm's lead therapeutic programs organized around unmet needs in asthma and atopic dermatitis treatment, the new entity is retaining the Pantherics Incorporated name and now has facilities in La Jolla CA and Madison WI. The new entiity is undertaking preclinical studies of a new medication to control asthma without the use of inhalers - specifically allow ingrelative tissue selective targeting. GABAA receptor modulation can uniquely address diseases where inflammation, smooth muscle reactivity, and sensory nerve activation intersect, including pulmonary, gastrointestinal, bladder, and others.
